About Immunis.AI
Immunis.AI is a company based in Royal Oak (United States) founded in 2012. Immunis.AI has raised $22.2 million across 2 funding rounds from investors including Savitr Capital. Immunis.AI operates in a competitive market with competitors including Mirvie, MDxHealth, OncoCyte, Epic Sciences and Miroculus, among others.
- Headquarter Royal Oak, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$22.2 M (USD)
in 2 rounds
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Immunis.AI
Immunis.AI has successfully raised a total of $22.2M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Immunis.AI
Immunis.AI has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Savitr Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Savitr Capital is focused on direct capital investments.
|
Locked | Locked | Locked |
Investor details for Immunis.AI
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Immunis.AI
Investment portfolio details for Immunis.AI
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Immunis.AI
Detailed financials for Immunis.AI
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immunis.Ai Comparisons
Peer comparison for Immunis.AI
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Immunis.AI
Immunis.AI operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Mirvie, MDxHealth, OncoCyte, Epic Sciences and Miroculus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Non-invasive blood tests for prenatal fetal health predictions are offered.
|
|
| Locked | Locked | Locked |
Epigenetic tests for personalized cancer assessment and treatment.
|
|
| Locked | Locked | Locked |
Non-invasive diagnostic test solutions for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Non-invasive tests for detecting circulating tumor cells are provided.
|
|
| Locked | Locked | Locked |
MicroRNA profiling platform is developed to detect genes in samples.
|
|
| Locked | Locked | Locked |
Molecular diagnostic products for prostate cancer assessment are provided.
|
Detailed competitors of Immunis.AI
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immunis.Ai
Complete news archive for Immunis.AI
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immunis.AI
Immunis.AI was founded in 2012 and raised its 1st funding round 7 years after it was founded.
Immunis.AI is headquartered in Royal Oak, United States. It is registered at Royal Oak, Michigan, United States.
Christopher Thibodeau is the current CEO of Immunis.AI.
Immunis.AI is a funded company, having raised a total of $22.2M across 2 funding rounds to date.
Immunis.AI was founded in 2012 and is based in Royal Oak, United States, within the biotechnology sector focused on oncology diagnostics. A patented platform known as intelligentia is utilized to combine machine learning with disease-specific algorithms. Real-time surveillance of gene expression in monocytes and lymphocytes from patient samples is enabled, allowing detection of immune-response signal changes triggered by threats like cancer. Operations center on RNA expression analysis for early identification.
Immunis.AI has 1 investor. Key investors include Savitr Capital.